# Clinical Trial of HG146 Administered to Participants with Adenoid Cystic Carcinoma

Source: https://onco.cc/trials/nct06781567/  
OnCo record `nct06781567` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of HG146 in salivary gland cancers and head and neck squamous cell carcinoma, run by HitGen Inc., now recruiting.

## Summary

Clinical Trial of HG146 Administered to Participants with Adenoid Cystic Carcinoma is a phase 2 interventional study registered as NCT06781567 by HitGen Inc., with 140 participants planned, started 2024-12-13 and due to reach its primary completion in 2028-12-31. Interventions recorded: HG146.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06781567
- Phase: 2
- Setting: A Phase Il Clinical Study to Evaluate the Efficacy and Safety of HG146 Capsules in Participants with Recurrent or Metastatic Adenoid Cystic Carcinoma.
- Sponsor: HitGen Inc.
- Enrolled: 140

## Sources

- ClinicalTrials.gov NCT06781567: https://clinicaltrials.gov/study/NCT06781567

## Connected records

- cancers: [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [Salivary gland cancers](https://onco.cc/cancers/salivary-gland/)

---
JSON: https://onco.cc/api/v1/entities/nct06781567.json